Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024	Baseline up to 50 weeks
Secondary	Change in PSA Response	Baseline to up to 3 years	PSA doubling time, PSA slope
Secondary	Duration of PSA Response	Up to 3 years
Secondary	Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4	Up to 3 years	The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.
Secondary	Immune Response	Week 6
Secondary	Immune Response	Week 10
Secondary	Immune Response	Week 26
Secondary	Immune Response	Week 50
Secondary	Immune Response (Arm 2 Only)	Week 0
Secondary	Objective Response Rates (Partial or Complete)	Up to 3 years
Secondary	Overall Survival	Up to 3 years
Secondary	Progression-free Survival	Up to 3 years
Secondary	Time to PSA Progression	Up to 3 years
Other	Effects of Tasquinimod on the Inhibition of Immune Cells	Up to week 50

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02159950/registered